Gokhan Koyluoglu

Gokhan Koyluoglu

Auto-generated profile, based on publicly available information

Gokhan Koyluoglu

Department of Pediatric Surgery, Cumhuriyet University School of Medicine, Sivas, Turkey

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Surgery
Verified
Journal Article
Closed access
LCLevent Cankorkmaz
Levent Cankorkmaz
HOHatice Ozer
Hatice Ozer
CGCengiz Guney
Cengiz Guney
MAMehmet H. Atalar
Mehmet H. Atalar
MAMehmet S. Arslan
Mehmet S. Arslan
GKGokhan Koyluoglu
Gokhan Koyluoglu

31 March 2005 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
CCCanan Ceran
Canan Ceran
IOIbrahim Oztoprak
Ibrahim Oztoprak
LCLevent Cankorkmaz
Levent Cankorkmaz
CGCesur Gumuş
Cesur Gumuş
TYturan yıldız
turan yıldız
GKGokhan Koyluoglu
Gokhan Koyluoglu

1 December 2004 in Journal of Surgical Research
Verified
Journal Article
Closed access
MAMehmet Arpacık
Mehmet Arpacık
CCCanan Ceran
Canan Ceran
TKTijen Kaya
Tijen Kaya
BKBarıš Karadas
Barıš Karadas
BSBülent Sarac
Bülent Sarac
GKGökhan Koyluoğlu
Gökhan Koyluoğlu

1 June 2001 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
GKG. Köylüoğlu
G. Köylüoğlu
MBM.Z. Bakici
M.Z. Bakici
ŞEŞ. Elagöz
Ş. Elagöz
MAM. Arpacik
M. Arpacik

1 October 2002 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
PDF file
CCCanan Ceran
Canan Ceran
GKGökhan Köylüoğlu
Gökhan Köylüoğlu
KSKaan Sönmez
Kaan Sönmez

11 April 2016 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
TKTijen Temiz Kaya
Tijen Temiz Kaya
AAAhmet Altun
Ahmet Altun
NTNergiz Hacer Turgut
Nergiz Hacer Turgut
HAHilmi Ataseven
Hilmi Ataseven
GKGokhan Koyluoglu
Gokhan Koyluoglu
Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells Colorectal cancer;motesanib;multikinase inhibitor;COX-2 inhibition; In the present study, we investigated the effects of motesanib (AMG 706), a multikinase inhibitor alone and in combination with DuP-697, an irreversible selective inhibitor of COX-2, on cell proliferation, angiogenesis, and apoptosis induction in a human colorectal cancer cell line (HT29). Real time cell analysis (RTCA, Xcelligence system) was used to determine the effects on colorectal cancer cell proliferation. Apoptosis was assessed with annexin V staining and angiogenesis was determined with chorioallantoic membrane model. We found that motesanib alone exerted antiproliferative, antiangiogenic and apoptotic effects on HT29 colorectal cancer cells. Combination with DUP-697 increased the antiproliferative, antiangiogenic and apoptotic effects. Results of this study indicate that motesanib may be a good choice in treatment of colorectal tumors. In addition, the increased effects of combination of motesanib with DuP-697 raise the possibility of using lower doses of these drugs and therefore avoid/minimize the dose-dependent side effects generally observed.